HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

 215.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 286.00
  • 52 Week Low: 189.00
  • Currency: UK Pounds
  • Shares Issued: 872.17m
  • Volume: 48
  • Market Cap: £1,875.16m
  • RiskGrade: 226

Latest ShareCast News

Hutchmed enrols last patient in phase three lung cancer trial

By Josh White

Date: Wednesday 05 Nov 2025

(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment for its global phase three 'Saffron' trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients with MET overexpression or amplification who had progressed following Tagrisso treatment.

Hutchmed takes wraps off expanding oncology pipeline

By Josh White

Date: Monday 03 Nov 2025

(Sharecast News) - Hutchmed unveiled new details on its expanding oncology pipeline and research strategy, including the launch of its next-generation antibody-targeted therapy conjugate (ATTC) platform, during its annual research and development update on Monday.

Hutchmed upbeat on preclinical data for novel cancer therapy

By Josh White

Date: Thursday 23 Oct 2025

(Sharecast News) - Hutchmed China reported preclinical data on Thurdsay, showing strong anti-tumour activity for its novel cancer therapy HMPL-A251, the first investigational drug to emerge from the company's proprietary Antibody-Targeted Therapy Conjugate (ATTC) platform.

Hutchmed to present new and updated clinical data 05-Sep-2025 ShareCast
Hutchmed enrols last patient in phase 3 lung can... 20-Aug-2025 ShareCast
Hutchmed to get milestone payment after China dr... 30-Jun-2025 ShareCast
Hutchmed new drug application accepted in China 05-Jun-2025 ShareCast
Hutchmed China upbeat on results from lung cance... 02-Jun-2025 ShareCast
Hutchmed enrols patients for phase two savolitin... 22-Apr-2025 ShareCast
Hutchmed renal cell carcinoma trial meets primar... 19-Mar-2025 ShareCast
Hutchmed announces progress, hits milestone with... 02-Jan-2025 ShareCast
Hutchmed to receive $10m milestone payment from ... 13-Dec-2024 ShareCast
Hutchmed lung cancer therapy gets breakthrough d... 12-Dec-2024 ShareCast
Hutchmed endometrial cancer treatment gets condi... 03-Dec-2024 ShareCast
Hutchmed partner launches Fruzaqla in Japan 22-Nov-2024 ShareCast
Hutchmed to receive $20m Fruzaqla milestone paym... 31-Oct-2024 ShareCast
Hutchmed reports positive results from AstraZene... 16-Oct-2024 ShareCast
Hutchmed partner Takeda gets Japanese approval f... 24-Sep-2024 ShareCast
Hutchmed to present new and updated clinical tri... 09-Sep-2024 ShareCast
Hutchmed withdraws supplemental new drug applica... 30-Aug-2024 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HCM Market Data

Currency UK Pounds
Share Price 215.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 286.00
52 Week Low 189.00
Volume 48
Shares Issued 872.17m
Market Cap £1,875.16m
RiskGrade 226

HCM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
43.68% below the market average43.68% below the market average43.68% below the market average43.68% below the market average43.68% below the market average
31.71% below the sector average31.71% below the sector average31.71% below the sector average31.71% below the sector average31.71% below the sector average
Price Trend
21.97% below the market average21.97% below the market average21.97% below the market average21.97% below the market average21.97% below the market average
27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average
Income Not Available
Growth
44.06% below the market average44.06% below the market average44.06% below the market average44.06% below the market average44.06% below the market average
86.21% below the sector average86.21% below the sector average86.21% below the sector average86.21% below the sector average86.21% below the sector average

HCM Dividends

No dividends found

Trades for 04-Dec-2025

Time Volume / Share Price
09:56 5 @ 218.80p
08:00 1 @ 223.00p
08:00 42 @ 223.00p

HCM Key Personnel

Chair Dan Eldar
CEO Weiguo Su

Top of Page